Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

This review discusses the dermatologic side effects and potential therapeutic benefits of GLP-1 receptor agonists, such as facial fat loss and wound healing, emphasizing the need for further research.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This research observed that oxytocin receptor agonists WAY267464 and LIT001 increased hair growth-related gene expression in human dermal papilla cells and significantly promoted hair follicle sprouting in vitro, suggesting their potential as hair growth agents targeting OXTR for alopecia treatment.

This editorial examines how GLP-1 receptor agonists, providing significant weight loss and cardiovascular benefits, can be integrated into a comprehensive obesity treatment alongside diet and lifestyle changes, but highlights the need for further guidance on their real-world application and multidisciplinary care.

This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.

This study found that topical phenylephrine, an α1-AR agonist, significantly reduced hair shedding and increased epilation force threshold in women experiencing traction alopecia during cosmetic procedures.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

This study found that oral administration of 7, 8–dihydroxyflavone in guinea pigs improved recovery from gentamicin-induced vestibular damage, suggesting potential therapeutic use for vestibular dysfunction in humans.

This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.

This case study details a 57-year-old woman with symptoms of androgen excess, including rapid hair growth and temporal balding, alongside abnormal testosterone levels and a history of chronic renal failure.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study demonstrated that the biomimetic peptide PTP20 may help preserve hair pigmentation and reduce greying by enhancing melanocyte function and increasing melanin production in human hair follicles.

This study suggests that the InlB321/15 protein may accelerate wound healing by increasing cell proliferation and reducing wound closure time in both cell culture and mouse models.

In this case study, a 25-year-old female with premature hair graying achieved over 90% conversion of gray hair to black hair after 5 months of treatment with a topical peptide solution and hair supplements.

In human hair follicle cultures, this study found that cyclohexyl salicylate, an OR2A4/7 agonist, promoted hair growth by delaying catagen development and expanding epithelial stem cell progeny, suggesting its potential as a non-drug hair loss treatment.

This laboratory study concluded that TRPA1 and TRPV1 channels do not play a role in mechanotransduction processes in slowly adapting type II mechanoreceptors in isolated rat sinus hair follicles.

This study did not find any significant effects of estradiol or its antagonists on hair growth in two common mouse strains, challenging previous results reported by Oh and Smart.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

GLP-1 RA medications may be linked to hair loss.

In this study, researchers explored whether minoxidil, a common treatment for androgenetic alopecia, may have estrogenic activity and found preliminary evidence suggesting it could act as a partial agonist of Estrogen Receptor α (ERα).